These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8765411)

  • 1. Antitumor and antimetastatic effects of interleukin 12.
    Fujiwara H; Hamaoka T
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S22-6. PubMed ID: 8765411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.
    Zou JP; Yamamoto N; Fujii T; Takenaka H; Kobayashi M; Herrmann SH; Wolf SF; Fujiwara H; Hamaoka T
    Int Immunol; 1995 Jul; 7(7):1135-45. PubMed ID: 8527411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes.
    Mu J; Zou JP; Yamamoto N; Tsutsui T; Tai XG; Kobayashi M; Herrmann S; Fujiwara H; Hamaoka T
    Cancer Res; 1995 Oct; 55(19):4404-8. PubMed ID: 7671253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
    Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
    Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12.
    Yu WG; Yamamoto N; Takenaka H; Mu J; Tai XG; Zou JP; Ogawa M; Tsutsui T; Wijesuriya R; Yoshida R; Herrmann S; Fujiwara H; Hamaoka T
    Int Immunol; 1996 Jun; 8(6):855-65. PubMed ID: 8671675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer.
    Oshikawa K; Rakhmilevich AL; Shi F; Sondel PM; Yang N; Mahvi DM
    Hum Gene Ther; 2001 Jan; 12(2):149-60. PubMed ID: 11177552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-tumor effects of IL-12 involve enhanced IFN-gamma production by anti-tumor T cells, their accumulation to tumor sites and in situ IFN-gamma production.
    Fujiwara H; Hamaoka T
    Leukemia; 1997 Apr; 11 Suppl 3():570-1. PubMed ID: 9209457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways.
    Yu WG; Ogawa M; Mu J; Umehara K; Tsujimura T; Fujiwara H; Hamaoka T
    J Leukoc Biol; 1997 Oct; 62(4):450-7. PubMed ID: 9335314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of peritumoral stroma required for IL-12 induced tumor regression depends on the T cell/IFN-gamma-involving host-tumor interaction.
    Uekusa Y; Ogawa M; Gao P; Iwasaki M; Ono S; Tsujimura T; Nakazawa M; Sakuda M; Clancy B; Fujiwara H; Hamaoka T
    Int J Oncol; 2000 Apr; 16(4):805-14. PubMed ID: 10717251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12.
    Ogawa M; Tsutsui T; Zou JP; Mu J; Wijesuriya R; Yu WG; Herrmann S; Kubo T; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Jun; 57(11):2216-22. PubMed ID: 9187124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models.
    Iwasaki M; Yu WG; Uekusa Y; Nakajima C; Yang YF; Gao P; Wijesuriya R; Fujiwara H; Hamaoka T
    Int Immunol; 2000 May; 12(5):701-9. PubMed ID: 10784616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of interleukin 12 in preclinical models.
    Brunda MJ; Luistro L; Rumennik L; Wright RB; Dvorozniak M; Aglione A; Wigginton JM; Wiltrout RH; Hendrzak JA; Palleroni AV
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S16-21. PubMed ID: 8765410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
    Nastala CL; Edington HD; McKinney TG; Tahara H; Nalesnik MA; Brunda MJ; Gately MK; Wolf SF; Schreiber RD; Storkus WJ
    J Immunol; 1994 Aug; 153(4):1697-706. PubMed ID: 7913943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of IL-12 induces a CD3+ CD4- CD8- B220+ lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells.
    Tsutsui T; Mu J; Ogawa M; Yu WG; Suda T; Nagaga S; Saji F; Murata Y; Fujiwara H; Hamaoka T
    J Immunol; 1997 Sep; 159(6):2599-605. PubMed ID: 9300678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
    Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
    Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres.
    Sabel MS; Arora A; Su G; Griffith KA; Mathiowitz E; Reineke JJ; Chang AE
    J Immunother; 2007; 30(8):808-16. PubMed ID: 18049332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.
    Hafner M; Falk W; Echtenacher B; Männel DN
    Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
    J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.